Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Alain H. Rook, Joel M. Gelfand, Maria Wysocka, Andrea B. Troxel, Bernice Benoit, Christian Surber, Rosalie Elenitsas, Marie A. Buchanan, Deborah S. Leahy, Rei Watanabe, Ilan R. Kirsch, Ellen J. Kim, Rachael A. Clark

Blood (2015) 126 (12): 1452–1461.

https://doi.org/10.1182/blood-2015-02-630335

Published: 2015

Includes: Supplemental data

Journal Articles

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell D. Coll, Hasan Rajabi, Athalia Pyzer, Michal Bar-Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Kufe, David Avigan

Blood (2015) 126 (3): 354–362.

https://doi.org/10.1182/blood-2015-02-628149

Published: 2015

Includes: Supplemental data

Journal Articles

MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Salvia Jain, MD, Maroof Alam, PhD, Hasan Rajabi, PhD, Dina Stroopinsky, PhD, Li Yin, PhD, Jacalyn Rosenblatt, MD, Kristen A Palmer, Maxwell Douglas Coll, Athalia Rachel Pyzer, MD, Katarina Luptakova, MD, Jon Arnason, MD, Robin Joyce, MD, Michal Bar-Natan, MD, Poorvi Somaiya, MSc, Rachael A Clark, MDPhD, Thomas S. Kupper, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 808.

https://doi.org/10.1182/blood.V124.21.808.808

Published: 2014

Journal Articles

High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-Cell Lymphoma

Ilan Kirsch, MD, David W Williamson, PhD, James Krueger, MD PhD, Jessica Teague, PhD, Christopher Elco, MD PhD, Harlan Robins, PhD, Thomas S. Kupper, MD, Rachael A Clark, MDPhD

Blood (2014) 124 (21): 1683.

https://doi.org/10.1182/blood.V124.21.1683.1683

Published: 2014

Journal Articles

Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma

Filiberto Cedeno-Laurent, Rei Watanabe, Jessica E. Teague, Thomas S. Kupper, Rachael A. Clark, Charles J. Dimitroff

Blood (2012) 119 (15): 3534–3538.

https://doi.org/10.1182/blood-2011-12-396457

Published: 2012

Includes: Supplemental data

Journal Articles

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma

Rachael A. Clark, Jeffrey B. Shackelton, Rei Watanabe, Adam Calarese, Kei-ichi Yamanaka, James J. Campbell, Jessica E. Teague, Helen P. Kuo, DirkJan Hijnen, Thomas S. Kupper

Blood (2011) 117 (6): 1966–1976.

https://doi.org/10.1182/blood-2010-05-287664

Published: 2011

Includes: Supplemental data

Journal Articles

Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

James J. Campbell, Rachael A. Clark, Rei Watanabe, Thomas S. Kupper

Blood (2010) 116 (5): 767–771.

https://doi.org/10.1182/blood-2009-11-251926

Published: 2010

Journal Articles

Sezary Syndrome Is a Malignancy of Central Memory T Cells with Skin Homing Properties, While Mycosis Fungoides Is a Malignancy of Skin Homing Effector Memory T Cells.

James Campbell, PhD, Rachael A Clark, MD, PhD, Thomas S. Kupper, MD

Blood (2009) 114 (22): 3954.

https://doi.org/10.1182/blood.V114.22.3954.3954

Published: 2009

Journal Articles

Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL).

David C. Fisher, MD, Marianne Tawa, Michele Walsh, Nurse, Practioner, Rachael A Clark, MD, PhD, Thomas S. Kupper, MD

Blood (2009) 114 (22): 3748.

https://doi.org/10.1182/blood.V114.22.3748.3748

Published: 2009

Journal Articles

IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin

Rachael A. Clark, Thomas S. Kupper

Blood (2006) 109 (1): 194–202.

https://doi.org/10.1182/blood-2006-02-002873

Published: 2006

Includes: Supplemental data

NARROW

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-Cell Lymphoma

Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma

Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

Sezary Syndrome Is a Malignancy of Central Memory T Cells with Skin Homing Properties, While Mycosis Fungoides Is a Malignancy of Skin Homing Effector Memory T Cells.

Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL).

IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only